| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MSI2 |
| Uniprot No | Q96DH6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-328aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMEANGSQGTSGSANDSQHDPGKMFIGG LSWQTSPDSLRDYFSKFGEIRECMVMRDPTTKRSRGFGFVTFADPASVDK VLGQPHHELDSKTIDPKVAFPRRAQPKMVTRTKKIFVGGLSANTVVEDVK QYFEQFGKVEDAMLMFDKTTNRHRGFGFVTFENEDVVEKVCEIHFHEINN KMVECKKAQPKEVMFPPGTRGRARGLPYTMDAFMLGMGMLGYPNFVATYG RGYPGFAPSYGYQFPGFPAAAYGPVAAAAVAAARGSGSNPARPGGFPGAN SPGPVADLYGPASQDSGVGNYISAASPQPGSGFGHGIAGPLIATAFTNGY H |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MSI2重组蛋白的虚构参考文献示例(仅供格式参考，实际文献需通过学术数据库查询)：
1. **标题**: "MSI2重组蛋白调控白血病干细胞自我更新的分子机制"
**作者**: Smith J, et al.
**摘要**: 本研究通过重组MSI2蛋白体外实验，揭示了其通过结合Notch信号通路mRNA增强白血病干细胞干性维持的作用，为靶向MSI2的癌症治疗提供依据。
2. **标题**: "重组人MSI2蛋白的晶体结构及其RNA结合特性分析"
**作者**: Chen L, et al.
**摘要**: 报道了MSI2重组蛋白的纯化与晶体结构解析，发现其RNA结合域特异性识别富含GU重复序列的靶标，并验证了关键氨基酸突变对功能的破坏效应。
3. **标题**: "MSI2重组蛋白在神经干细胞分化中的动态翻译调控"
**作者**: Yamamoto S, et al.
**摘要**: 利用重组MSI2蛋白进行体外RNA结合实验，证明其通过抑制Numb mRNA翻译维持神经干细胞未分化状态，并揭示了其磷酸化修饰对功能的调节作用。
4. **标题**: "靶向MSI2重组蛋白的小分子抑制剂筛选及抗肿瘤活性研究"
**作者**: Gupta R, et al.
**摘要**: 基于重组MSI2蛋白的高通量药物筛选平台，鉴定出可阻断MSI2-RNA相互作用的先导化合物，并在结肠癌模型中显示出抑制肿瘤生长的效果。
(注：以上文献为示例性质，具体研究需查阅真实数据库如PubMed、Web of Science等。)
**Background of MSI2 Recombinant Protein**
The Musashi-2 (MSI2) protein, a member of the RNA-binding Musashi family, plays critical roles in post-transcriptional gene regulation by binding to target mRNAs to influence translation, stability, and localization. Structurally, MSI2 contains two conserved RNA recognition motifs (RRMs) that mediate interactions with specific sequences, often in the 3'-untranslated regions (UTRs) of mRNAs. It is highly expressed in stem/progenitor cells, where it supports self-renewal and maintenance by repressing differentiation-promoting genes.
Dysregulation of MSI2 is implicated in various cancers, including leukemia, glioblastoma, and solid tumors. Overexpression of MSI2 correlates with poor prognosis, enhanced tumor aggressiveness, and therapy resistance. It drives oncogenic pathways, such as Wnt/β-catenin and MYC, and promotes epithelial-mesenchymal transition (EMT) and metastasis. In hematological malignancies, MSI2 sustains leukemic stem cell populations, making it a therapeutic target.
Recombinant MSI2 proteins are engineered to study its molecular functions, interactions, and therapeutic potential. Produced via bacterial or eukaryotic expression systems, these proteins retain RNA-binding activity and are used in *in vitro* assays, structural studies, and inhibitor screening. Tagged versions (e.g., His-, GST-tagged) facilitate purification and detection. Research on MSI2 recombinant proteins aids in elucidating its role in cancer biology and developing targeted therapies, such as small-molecule inhibitors or RNA-based approaches, to disrupt its oncogenic activity.
×
